Abstract:About one third of patients with non-small cell lung cancer presents with stage III NSCLC at diagnosis 1 . The standard of care for patients with unresectable stage III NSCLC is concurrent chemoradiation (CCRT) followed by adjuvant durvalumab 2 . Adjuvant durvalumab led to a 5-year overall survival (OS) and progression free survival (PFS) rates of 42.9% and 33.1% respectively 3 .For patients with resectable stage III NSCLC the standard of care is represented by surgery and (neo) adjuvant or perioperative immune checkpoint blockers (ICB), leading to a 2 years OS rate up to 80% and 2 years PFS rate up to 65% [4][5][6][7] . For patients with stage III NSCLC harboring actionable driver alterations (AGA) radical treatment should be coupled with (neo)adjuvant target treatments, if available 8,9 . Despite the great survival improvements achieved in the recent years, most of the patients who are diagnosed with stage III NSCLC still face disease recurrence (PD). Moreover, many open questions and unmet clinical need are present in this setting 10,11 .The manuscripts included in the present Research Topic try to address open questions and present new evidence about the treatment options for patients with stage III NSCLC.Yu and colleagues (https://doi.org/10.3389/fonc.2024.1351359 ) performed a meta-analysis based on three randomized controlled trials (RCTs) investigating perioperative ICB for stage II-III NSCLC.Their findings showed that perioperative ICB combined with CT led to better OS, PFS and ORR compared to CT only. At the same time no statistically significant differences in terms of grade≥3 adverse events were noted. This meta-analysis confirmed that the use of ICB in the peri-operative setting is the new gold-standard. Qiao et al ( https://doi.org/10.3389/fonc.2023.1198768 ) investigated the effectiveness and safety of Shenqi Fuzheng (SFI) injection combined with platinumbased chemotherapy for patients with NSCLC. SFI is an extraction of Codonopsis pilosula and Astragalus membranaceus, which reduces oxidative stress. Their findings are based on 44RCT involving 3475 patients. They showed that SFI significantly reduced CT adverse events (bone marrow depression; nausea; vomiting and diarrhea). This meta-analysis investigates the often neglected research topic of reducing side effects. This is paramount in stage III NSCLC since toxicity represents a main issue in radical treatments in this setting. Shendou Li and colleagues (https://doi.org/10.3389/fonc.2024.1306311 ) addressed the question whether ICB retreatment might be effective for patients with NSCLC. This retrospective study included 165 patients who were pretreated with ICB: 38.2% received ICB retreatment with atezolizumab while 12.7% and 49.1% received docetaxel and docetaxel+ramucirumab respectively. Patients treated with atezolizumab achieved a significantly better mOS compared to the other two groups (17.7 vs. 7.7 months for docetaxel [p=0.008] and vs 8.9 months for docetaxel+ramucirumab [p=0.047]). These results are particularly interesting since patients with stage III NSCLC receive adjuvant ICB as standard of care but there are no robust data about a ICB retreatment at PD. In the retrospective study presented by Borghetti et al. (N=85), safety and effectiveness of adjuvant durvalumab in a real life scenario were investigated (https://doi.org/10.3389/fonc.2023.1208204 ). Two-year OS was 69.4% in the durvalumab group and 47.9% in the non-durvalumab group (p = 0.015). Two-year PFS was 54.4% in the durvalumab group and 24.2% in the non-durvalumab group (p = 0.007). Of note, 79% had a PDL-1 positive NSCLC and in the remaining 21% PDL-1 status was unknown. A retrospective multicenter analysis (N=1874) described the pattern of treatments in the Asian population (https://doi.org/10.3389/fonc.2023.1117348 ). This study enrolled consecutive patients, from 57 centers, diagnosed with de novo locally advanced stage III NSCLC. CCRT was the most common treatment choice (34%) followed by curative surgery (23%), systemic treatments (21%) and sCRT (11%). The possible different approaches used in this wide cohort to treat stage III highlight that multidisciplinary discussion is paramount in this setting. Finally two studies presented in this research topic investigated new tools for personalizing the treatment of patients with stage III NSCLC. Yang and colleagues (https://doi.org/10.3389/fonc.2023.1158104 ) presented the data about 124 patients with stage III-N2 disease treated with surgery, adjuvant CT and post-operative RT (PORT). They showed that the presence of estrogen receptor was a significant negative prognostic factor, in terms of OS and PFS. These findings bring to light a possible new prognostic factor, possibly helping in

Rethinking the definition of stage IV disease in adrenocortical carcinoma: Assessing the impact of clinical lymph node positive disease.

Prognostic Impact of Lymphadenectomy on Outcomes of Sublobar Resection for Stage IA Non–small Cell Lung Cancer ≤2 Cm

Differences in life expectancy of adrenocortical carcinoma patients vs. age‑ and sex-matched population controls

555. SUPRACLAVICULAR NODE INVOLVEMENT, A NODAL OR METASTATIC DISEASE? - A 10-YEAR EXPERIENCE IN ESOPHAGEAL CARCINOMA AT A TERTIARY REFERRAL CENTRE

Impact of Lymphadenectomy Extent on Immunotherapy Efficacy in Postresectional Recurred Non-Small Cell Lung Cancer: a Multi-Institutional Retrospective Cohort Study.

The clinical utility of ‘GRAS’ parameters in stage I–III adrenocortical carcinomas: long-term data from a high-volume institution

Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?

The diagnosis and treatment of adrenocortical carcinoma:report of 39 cases

Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer

Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy

Surgical Intervention May Be a Therapeutic Option for NSCLC Patients with AJCC Stage IV: a Large Population-Based Study.

EP333/#110 Stage IVB Epithelial Ovarian Cancer with Isolated Distant Lymph Node Metastases: Should a New Substage Be Created? A Multi-Institutional Analysis

Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival

Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma

Outcomes and Prognostic Factors in Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy

Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer

Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC

“Expression and prognostic relevance of PD-1, PD-L1 and CTLA-4 immune checkpoints in adrenocortical carcinoma”

A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.

Impact of Lymph Node Dissection for Patients with Clinically Node-Negative Intrahepatic Cholangiocarcinoma: A Multicenter Cohort Study

Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study